Genzyme Corp

In operation since 1981, Genzyme Corporation is one of the leading biotechnology companies in the world. The company employs a staff of more than 12,000 people and manages over 85 locations in nearly 40 countries. It focuses on the areas of hematologic oncology, biosurgery, transplant, genetic diseases, and cardiometabolic and renal. Genzyme Corporation offers Fabrazyme, which is a solution for intravenous infusion. The company also provides Fabrazyme, Renagel, Renvela and Hectorol. It offers solutions for the medical and patient communities. In addition, Genzyme Corporation offers Synvisc, which is a viscosupplementation treatment for relieving knee pain associated with osteoarthritis. The company provides Sepra, which is a line of hyaluronic acid-based products.

Fresenius Medical Care North America is part of Fresenius Medical Care, one of the world's largest, integrated providers of products and services for individuals with chronic kidney failure, a condition that affects more than 1.5 million individuals worldwide. Through its network of over 2,220 dialysis clinics in North America, Europe, Latin America and Asia-Pacific, Fresenius Medical Care provides dialysis treatment to 172,227 patients around the globe. Fresenius Medical Care is also the world's largest provider of dialysis products, such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care can trace its roots back to 1462, when The Fresenius family assumed ownership of Hirsch Pharmacy in Frankfurt, Germany. Approximately two-thirds of the company's research and development activities are based in Germany and one-third in North America. The company holds rights to more than 1,100 patents and patent applications relating to dialysis technology in major markets and own trademarks throughout the world.

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.